The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BridgeBio Pharma wasn’t one of them. The 10 stocks that made the cut ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public.

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

The pace of issuance in the US investment-grade corporate bond primary slowed today, with just five offerings expected to price, joining the 23 issues already sold this week. The high-yield primary is ...